STLN insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Virnich Daniel Chief Executive Officer · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | Other transactionFiling detailsSEC transaction code J Common Stock · Direct ownership · Reported balance after transaction: 2332064 · Reflects shares required to be sold pursuant to a sell-to-cover transaction in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units, mandated by the Issuer and does not reflect a discretionary trade by the Reporting Person. | 2026-11-17 | 2026-11-19 | 5,102 shares/units | SEC 4 | Follow |
| Podnos Yale Chief Medical Officer · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | Other transactionFiling detailsSEC transaction code J Common Stock · Direct ownership · Reported balance after transaction: 257486 · Reflects shares required to be sold pursuant to a sell-to-cover transaction in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units, mandated by the Issuer and does not reflect a discretionary trade by the Reporting Person. | 2026-11-17 | 2026-11-19 | 1,271 shares/units | SEC 4 | Follow |
| Carter Robert Ross Chief Financial Officer · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | Other transactionFiling detailsSEC transaction code J Common Stock · Direct ownership · Reported balance after transaction: 414663 · Reflects shares required to be sold pursuant to a sell-to-cover transaction in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units, mandated by the Issuer and does not reflect a discretionary trade by the Reporting Person. | 2026-11-17 | 2026-11-19 | 138 shares/units | SEC 4 | Follow |
| Podnos Yale Chief Medical Officer · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | Other transactionFiling detailsSEC transaction code J Common Stock · Direct ownership · Reported balance after transaction: 258757 · Reflects shares required to be sold pursuant to a sell-to-cover transaction in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units, mandated by the Issuer and does not reflect a discretionary trade by the Reporting Person. | 2026-11-12 | 2026-11-17 | 770 shares/units | SEC 4 | Follow |
| Chernett Jorey 10% owner · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | BuyFiling detailsSEC transaction code P Original filed 2026-11-12 Call Option (STLN 19FEB27 $4C) · Derivative security · Direct ownership · Reported balance after transaction: 6391 · SEC code covers open-market or private transactions · The reported transaction is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transaction, which the reporting person intends to disgorge to the Issuer. · This Form 4/A is being filed solely to indicate that the Reporting Person is no longer subject to Section 16 reporting obligations and constitutes an exit filing for the Reporting Person. | 2026-11-11 | 2026-11-13 | 1,391 shares/units | SEC 4/A Amendment | Follow |
| Chernett Jorey 10% owner · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | BuyFiling detailsSEC transaction code P Call Option (STLN 19FEB27 $4C) · Derivative security · Direct ownership · Reported balance after transaction: 6391 · SEC code covers open-market or private transactions · The reported transaction is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transaction, which the reporting person intends to disgorge to the Issuer. | 2026-11-11 | 2026-11-12 | 1,391 shares/units | SEC 4 | Follow |
| Chernett Jorey 10% owner · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | BuyFiling detailsSEC transaction code P Call Option (STLN 21MAY27 $5C) · Derivative security · Direct ownership · Reported balance after transaction: 7000 · SEC code covers open-market or private transactions · The reported transactions are matchable transactions subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. | 2026-11-10 | 2026-11-10 | 7,000 shares/units | SEC 4 | Follow |
| Chernett Jorey 10% owner · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | BuyFiling detailsSEC transaction code P Call Option (STLN 19FEB27 $5C) · Derivative security · Direct ownership · Reported balance after transaction: 7500 · SEC code covers open-market or private transactions · The reported transactions are matchable transactions subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. · The price reported in Column 8 is a weighted average price. These Call Options were purchased in multiple transactions at prices ranging from $0.4998 to $0.55, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Call Options purchased at each separate price such Call Options were purchased. | 2026-11-09 | 2026-11-10 | 7,500 shares/units | SEC 4 | Follow |
| Chernett Jorey 10% owner · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | BuyFiling detailsSEC transaction code P Call Option (STLN 19FEB27 $4C) · Derivative security · Direct ownership · Reported balance after transaction: 5000 · SEC code covers open-market or private transactions · The reported transactions are matchable transactions subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. | 2026-11-06 | 2026-11-10 | 5,000 shares/units | SEC 4 | Follow |
| Chernett Jorey 10% owner · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | BuyFiling detailsSEC transaction code P Call Option (STLN 20NOV26 $4C) · Derivative security · Direct ownership · Reported balance after transaction: 10000 · SEC code covers open-market or private transactions · The reported transactions are matchable transactions subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. | 2026-11-06 | 2026-11-10 | 10,000 shares/units | SEC 4 | Follow |
| Chernett Jorey 10% owner · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 7858091 · SEC code covers open-market or private transactions · The reported transactions are matchable transactions subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. · The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.53 to $3.91, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased. | 2026-11-09 | 2026-11-10 | ≈ $176,273.10 48,294 shares/units | SEC 4 | Follow |
| Chernett Jorey 10% owner · Starling Oncology, Inc. | STLN Starling Oncology, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 7809797 · SEC code covers open-market or private transactions · The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were sold in multiple transactions at prices ranging from $3.38 to $5.21, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price such shares were sold. · The reported transactions are matchable transactions subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer. | 2026-11-06 | 2026-11-10 | ≈ $11,375,733.39 2,851,061 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.